Review

Injectable Lipid-Lowering Therapies in Advanced Chronic Kidney Disease: Efficacy, Safety and the Dialysis Paradox.

A. Damianaki E. Stambolliu P. Iliakis Panagiotis Theofilis A. Vakka Evangelia Kalliakouda P. Patsalis D. Konstantinidis Dimitrios I. Petras

Aug 2026 · Cardiovascular Drugs and Therapy · 0 citations · 37 references

Medicine

TL;DR

Why injectable lipid-lowering therapies in advanced CKD merits serious consideration is highlighted - not only for their potent and durable lipid-lowering effects, but also for their ability to target other paths that contribute to the excess CV risk not captured by LDL alone.

DOI PubMed Semantic Scholar

View source

Similar papers

Review Open access Sep 2026

Injectable Lipid-Lowering Therapies Across the Chronic Kidney Disease Spectrum: Evidence, Safety, and a Stage-Specific Clinical Framework

A stage-specific framework for integrating injectable therapies into CKD pathways is proposed—covering patient selection, sequencing, monitoring and implementation—and outline priorities for CKD-enriched outcome trials, kidney-relevant endpoints, and the integration of emerging lipoprotein(a)-targeted injectables into...

J. Baharani, Sudarshan Ramachandran · Lipidology · 0 citations

Review Sep 2026

New pharmacologic and interventional horizons in hypertension and nondialysis chronic kidney disease: bridging innovation and clinical translation.

A comprehensive overview of emerging pharmacologic and interventional approaches for BP management in nondialysis CKD is provided, highlighting mechanism-driven innovations and their potential clinical translation.

A. Damianaki, P. Iliakis, A. Vakka et al. · Journal of Hypertension · 0 citations

Review Open access Aug 2026

Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health.

Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a 'triple threat' with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stres...

A. Forrest, P. Majety, Stéphanie B. Mayer et al. · Diabetes, obesity and metabo... · 0 citations

Review Aug 2026

[Treatment of Hypercholesterolemia in Chronic Kidney Disease: Rationale and Therapeutic Approaches from the Non-Dialysis Stage to Kidney Transplantation].

The role of low-density lipoprotein cholesterol (LDL-C) in the excess cardiovascular risk associated with CKD is addressed and the impact of both traditional and novel LDL-C-lowering therapies across the entire spectrum of CKD is examined.

R. Minutolo, M. Ravera, M. Cozzolino et al. · Giornale Italiano di Nefrolo... · 0 citations

Review Open access Sep 2026

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel.

Chronic kidney disease (CKD) and cardiovascular disease (CVD) are major causes of morbidity and mortality in people with type 2 diabetes (T2D). Contemporary CKD guidelines increasingly support incorporation of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as an additional pillar of cardiorenal therapy alongside...

E. Pedagogos, Roger Chen, Adam J. Nelson et al. · Internal medicine journal (P... · 0 citations

Open access Sep 2026

Incretin-based therapies in diabetic kidney disease: toward integrated cardio-kidney-metabolic disease modification.

Mechanical insights from translational studies further suggest that GLP-1 receptor activation promotes metabolic decongestion, improves intrarenal hemodynamics, and attenuates inflammatory and fibrotic pathways, with emerging signals for cardiovascular and renal benefit.

Yaeni Kim, Eun Young Lee · Kidney Research and Clinical... · 0 citations